Literature DB >> 29282226

Maternal and Fetal Outcomes of Pregnancies in Women with Atypical Hemolytic Uremic Syndrome.

Martina Gaggl1, Christof Aigner2, Dorottya Csuka3, Ágnes Szilágyi3, Zoltán Prohászka3, Renate Kain4, Natalja Haninger2, Maarten Knechtelsdorfer5, Raute Sunder-Plassmann6, Gere Sunder-Plassmann2, Alice Schmidt2.   

Abstract

Atypical HUS (aHUS) is a disorder most commonly caused by inherited defects of the alternative pathway of complement, or the proteins that regulate this pathway, and life-threatening episodes of aHUS can be provoked by pregnancy. We retrospectively and prospectively investigated 27 maternal and fetal pregnancy outcomes in 14 women with aHUS from the Vienna Thrombotic Microangiopathy Cohort. Seven pregnancies (26%) were complicated by pregnancy-associated aHUS (p-aHUS), of which three appeared to be provoked by infection, bleeding, and curettage, and three individuals were considered to have preeclampsia/HELLP syndrome before the definitive diagnosis of p-aHUS was made. Mutations in genes that encode the complement alternative pathway proteins or the molecules that regulate this pathway were detected in 71% of the women, with no relationship to pregnancy outcome. Twenty-one pregnancies (78%) resulted in a live birth, two preterm infants were stillborn, and four pregnancies resulted in early spontaneous abortions. Although short-term renal outcome was good in most women, long-term renal outcome was poor; among the 14 women, four had CKD stage 1-4, five had received a renal allograft, and three were dialysis-dependent at study end. We prospectively followed nine pregnancies of four women and treated six of these pregnancies with prophylactic plasma infusions (one pregnancy resulted in p-aHUS, one intrauterine fetal death occurred, and seven pregancies were uneventful). Our study emphasizes the frequency of successful pregnancies in women with aHUS. Close monitoring of such pregnancies for episodes of thrombotic microangiopathy is essential but, the best strategy to prevent these episodes remains unclear.
Copyright © 2018 by the American Society of Nephrology.

Entities:  

Keywords:  TMA; aHUS; atypical hemolytic uremic syndrome; complement-mediated; pregnancy

Mesh:

Year:  2017        PMID: 29282226      PMCID: PMC5827586          DOI: 10.1681/ASN.2016090995

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  54 in total

Review 1.  Chronic kidney disease in pregnancy.

Authors:  David Williams; John Davison
Journal:  BMJ       Date:  2008-01-26

2.  Eculizumab in pregnancy-associated atypical hemolytic uremic syndrome: insights for optimizing management.

Authors:  Erika De Sousa Amorim; Miquel Blasco; Luis Quintana; Manel Sole; Santiago Rodríguez de Cordoba; Josep Maria Campistol
Journal:  J Nephrol       Date:  2015-02-25       Impact factor: 3.902

3.  Pregnancy-associated hemolytic uremic syndrome revisited in the era of complement gene mutations.

Authors:  Fadi Fakhouri; Lubka Roumenina; François Provot; Marion Sallée; Sophie Caillard; Lionel Couzi; Marie Essig; David Ribes; Marie-Agnès Dragon-Durey; Frank Bridoux; Eric Rondeau; Veronique Frémeaux-Bacchi
Journal:  J Am Soc Nephrol       Date:  2010-03-04       Impact factor: 10.121

4.  Age-related penetrance of hereditary atypical hemolytic uremic syndrome.

Authors:  Maren Sullivan; Lisa A Rybicki; Aurelia Winter; Michael M Hoffmann; Stefanie Reiermann; Hannah Linke; Klaus Arbeiter; Ludwig Patzer; Klemens Budde; Bernd Hoppe; Martin Zeier; Karl Lhotta; Andreas Bock; Thorsten Wiech; Ariana Gaspert; Thomas Fehr; Magdalena Woznowski; Gani Berisha; Angelica Malinoc; Oemer-Necmi Goek; Charis Eng; Hartmut P H Neumann
Journal:  Ann Hum Genet       Date:  2011-09-12       Impact factor: 1.670

5.  Causes of alternative pathway dysregulation in dense deposit disease.

Authors:  Yuzhou Zhang; Nicole C Meyer; Kai Wang; Carla Nishimura; Kathy Frees; Michael Jones; Louis M Katz; Sanjeev Sethi; Richard J H Smith
Journal:  Clin J Am Soc Nephrol       Date:  2012-01-05       Impact factor: 8.237

6.  Differential impact of complement mutations on clinical characteristics in atypical hemolytic uremic syndrome.

Authors:  Anne-Laure Sellier-Leclerc; Veronique Fremeaux-Bacchi; Marie-Agnès Dragon-Durey; Marie-Alice Macher; Patrick Niaudet; Geneviève Guest; Bernard Boudailliez; François Bouissou; Georges Deschenes; Sophie Gie; Michel Tsimaratos; Michel Fischbach; Denis Morin; Hubert Nivet; Corinne Alberti; Chantal Loirat
Journal:  J Am Soc Nephrol       Date:  2007-06-28       Impact factor: 10.121

7.  A kidney biopsy is clearly mandatory to confirm the indication of plasma exchanges in adult haemolytic uraemic syndrome.

Authors:  O Pourrat; G Touchard; R Robert; P Badia; M Bauwens; T Hauet; D Patte
Journal:  Ann Med Interne (Paris)       Date:  1994

8.  Perspectives on Pregnancy in Women With CKD: A Semistructured Interview Study.

Authors:  Allison Tong; Mark A Brown; Wolfgang C Winkelmayer; Jonathan C Craig; Shilpanjali Jesudason
Journal:  Am J Kidney Dis       Date:  2015-10-06       Impact factor: 8.860

9.  Thrombotic thrombocytopenic purpura and pregnancy: presentation, management, and subsequent pregnancy outcomes.

Authors:  Marie Scully; Mari Thomas; Mary Underwood; Henry Watson; Katherine Langley; Raymond S Camilleri; Amanda Clark; Desmond Creagh; Rachel Rayment; Vickie Mcdonald; Ashok Roy; Gillian Evans; Siobhan McGuckin; Fionnuala Ni Ainle; Rhona Maclean; William Lester; Michael Nash; Rosemary Scott; Patrick O Brien
Journal:  Blood       Date:  2014-05-23       Impact factor: 22.113

10.  Genetic analysis of the complement factor H related 5 gene in haemolytic uraemic syndrome.

Authors:  G Monteferrante; S Brioschi; J Caprioli; G Pianetti; P Bettinaglio; E Bresin; G Remuzzi; M Noris
Journal:  Mol Immunol       Date:  2006-09-26       Impact factor: 4.407

View more
  23 in total

1.  Insights into pregnancy associated and atypical hemolytic uremic syndrome.

Authors:  Sophie Grand'Maison; Stephen Lapinsky
Journal:  Obstet Med       Date:  2018-07-12

2.  Corrigendum: Insights into pregnancy associated and atypical hemolytic uremic syndrome.

Authors: 
Journal:  Obstet Med       Date:  2018-12-13

3.  Thrombotic microangiopathy: Pregnancy outcomes in aHUS.

Authors:  Ellen F Carney
Journal:  Nat Rev Nephrol       Date:  2018-01-15       Impact factor: 28.314

Review 4.  Eculizumab in pregnancy: a narrative overview.

Authors:  Laura Sarno; Antonella Tufano; Giuseppe Maria Maruotti; Pasquale Martinelli; Mario M Balletta; Domenico Russo
Journal:  J Nephrol       Date:  2018-08-29       Impact factor: 3.902

Review 5.  Thrombotic microangiopathy in aHUS and beyond: clinical clues from complement genetics.

Authors:  Fadi Fakhouri; Véronique Frémeaux-Bacchi
Journal:  Nat Rev Nephrol       Date:  2021-05-05       Impact factor: 28.314

6.  Pregnancy in Women with Atypical Hemolytic Uremic Syndrome.

Authors:  Eric Rondeau; Gianluigi Ardissino; Marie-Pierre Caby-Tosi; Imad Al-Dakkak; Fadi Fakhouri; Benjamin Miller; Marie Scully
Journal:  Nephron       Date:  2021-09-07       Impact factor: 2.847

7.  How to evaluate and treat the spectrum of TMA syndromes in pregnancy.

Authors:  Marie Scully
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2021-12-10

8.  Postpartum atypical hemolytic uremic syndrome: Evaluating thrombotic microangiopathy in the pregnant woman.

Authors:  S So; E Fischer; M Gangadharan Komala; B Bose
Journal:  Obstet Med       Date:  2020-06-11

Review 9.  Membrane cofactor protein (MCP; CD46): deficiency states and pathogen connections.

Authors:  M Kathryn Liszewski; John P Atkinson
Journal:  Curr Opin Immunol       Date:  2021-05-15       Impact factor: 7.268

10.  Sex Differences in Clinical Presentation and Outcomes among Patients with Complement-Gene-Variant-Mediated Thrombotic Microangiopathy.

Authors:  Christof Aigner; Martina Gaggl; Renate Kain; Zoltán Prohászka; Nóra Garam; Dorottya Csuka; Raute Sunder-Plassmann; Leah Charlotte Piggott; Natalja Haninger-Vacariu; Alice Schmidt; Gere Sunder-Plassmann
Journal:  J Clin Med       Date:  2020-03-31       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.